Pre-Exposure Prophylaxis
FDA sets date for decision on twice-yearly shots to prevent HIV
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV infection and set a date of June 19 to decide on its approval, Gilead announced Tuesday.
Pemivibart only option against ‘false reassurance’ of reduced SARS-CoV-2 virulence
The next phase of pre-exposure prophylaxis against SARS-CoV-2 currently rests on the shoulders of a single monoclonal antibody product — but it may not be enough for immunocompromised populations.
No HIV vaccine on the horizon but research shows other tools, efforts are plentiful
Although there is still no HIV vaccine and no promising candidates in the pipeline, data published throughout 2024 show the significant impacts of prevention efforts and tools.
Does the world still need an HIV vaccine? Experts say yes
Fifteen years ago, an HIV vaccine trial conducted in Thailand and sponsored by the U.S. Army found something no other HIV vaccine trial ever had: a regimen that seemed to work.
VIDEO: What patients are saying about long-acting cabotegravir for HIV PrEP
LOS ANGELES —In this video from IDWeek, Vani Vannappagari, MBBS, PhD, MPH, global head of epidemiology and real-world evidence at ViiV Healthcare, discusses study findings demonstrating the effectiveness of cabotegravir for HIV prevention.
VIDEO: Lenacapavir shows ‘amazing’ results for resistant HIV
LOS ANGELES — Lenacapavir, the twice-yearly injectable HIV drug, could potentially transform HIV prevention if it is approved as PrEP, research has shown.
Despite improvement in new PrEP use, racial, ethnic ‘disparities still persist’
Access to pre-exposure prophylaxis remains insufficient, especially among Black, Hispanic and Medicare-insured populations, results of an analysis presented at IDWeek suggested.
‘Reassuring’: No interaction between long-acting HIV drug, contraceptives
LIMA, Peru — In a finding described as “reassuring,” researchers detected no interaction between the long-acting HIV prevention drug cabotegravir and hormonal contraceptives among women enrolled in a large trial.
Twice-yearly injections prevent HIV in another phase 3 trial
Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.
Study supports testing HIV PrEP users for STIs at 6 months instead of 3
Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.